Chordia Therapeutics Inc.

Chordia Therapeutics Inc. is a biotech company based in Fujisawa, Japan, that researches and develops anti-cancer drugs targeting RNA deregulation stress. Its pipeline includes CTX-712, a CLK inhibitor in Phase 1 clinical trials for relapsed or refractory malignant cancers; CTX-177, a small-molecule MALT1 inhibitor; CTX-439, a CDK12 inhibitor; and CRD-1968099, a GCN2 inhibitor. The company was incorporated in 2017.